MedTrace Logo

A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors

NCT03184870 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 332

Last updated 2025-10-09

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the safety profile, tolerability, drug levels, drug effects, and preliminary efficacy of BMS-813160 alone or in combination with either chemotherapy or nivolumab or chemotherapy plus nivolumab in participants with metastatic colorectal and pancreatic cancers.

Conditions

Interventions

DRUG

BMS-813160

Specified dose on specified days

BIOLOGICAL

Nivolumab

Specified dose on specified days

DRUG

Nab-paclitaxel

Specified dose on specified days

DRUG

Gemcitabine

Specified dose on specified days

DRUG

5-fluorouracil (5-FU)

Specified dose on specified days

DRUG

Leucovorin

Specified dose on specified days

DRUG

Irinotecan

Specified dose on specified days

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-08
Primary Completion
2023-04-06
Completion
2023-06-14
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Belgium
  • Canada
  • Germany
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03184870 on ClinicalTrials.gov